Quest Diagnostics: Catherine T. Doherty to retire in Jul 2027

What happened

• The filing says that on Oct 6, 2026, Quest Diagnostics announced that Catherine T. Doherty will retire in Jul 2027.
• The filing says that effective Nov 1, 2026, Ms. Doherty will transition to a new role as Executive Vice President with responsibilities including health systems, the Company’s joint venture with Corewell Health, and Project Nova (the multi-year project to modernize the Company’s “Order to Cash” business processes).
• The filing says the Compensation and Leadership Development Committee approved no change to Ms. Doherty’s annual base salary of $650,000 and no change to her annual incentive target of 80% of base salary, and approved an equity award under the Employee Long-Term Incentive Plan with a grant date of Nov 3, 2026 and a target value of $1,200,000 allocated 100% to restricted stock units.

Key details

• Retirement month: Jul 2027.
• Role transition effective: Nov 1, 2026.
• Annual base salary: $650,000.
• Annual incentive target: 80% of base salary.
• Equity award target value: $1,200,000, grant date Nov 3, 2026, 100% restricted stock units.

Why it may matter

• This filing was submitted under Item 5.02 (Departure of Directors or Certain Officers), which covers notices of departures, retirements, appointments and related compensation decisions reported by the company. The filing describes the role change, compensation decisions and an equity award. The filing does not show why the insider traded or why the company acted.